Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 11/20 | 0.52 |
| ▸ | GRM5 | P41594 | 10/20 | 0.52 |
| ▸ | WNT3A | P56704 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | CDK9 | P50750 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25480363 | 0.91 | GRM1 (0.51) | GRM1GRM5WNT3AGPR119CYP11B2 | |
| SCHEMBL23703974 | 0.88 | GRM1 (0.53) | GRM1GRM5WNT3AGPR119CYP11B2 | |
| SCHEMBL18409268 | 0.86 | GRM1 (0.52) | GRM1GRM5WNT3AGPR119CYP11B2 | |
| SCHEMBL18409265 | 0.86 | GRM1 (0.52) | GRM1GRM5WNT3AGPR119CYP11B2 | |
| SCHEMBL19203191 | 0.85 | GRM1 (0.53) | GRM1GRM5WNT3AGPR119CYP11B2 | |
| SCHEMBL23730448 | 0.82 | GRM1 (0.56) | GRM1GRM5WNT3AGPR119CYP11B2 | |
| SCHEMBL16844855 | 0.82 | GRM1 (0.48) | GRM1GRM5WNT3AGPR119CYP11B2 | |
| SCHEMBL23703330 | 0.81 | WNT3A (0.57) | GRM1GRM5WNT3AGPR119CYP11B2 | |
| SCHEMBL29723480 | 0.81 | WNT3A (0.57) | GRM1GRM5WNT3AGPR119CYP11B2 | |
| SCHEMBL23730450 | 0.81 | GRM1 (0.52) | GRM1GRM5WNT3AGPR119CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10472350-B2 | Soluble guanylate cyclase activators and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-12 | — | — | US | disclosed |
| US-10472350-B2 | Soluble guanylate cyclase activators and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-11-12 | — | — | US | disclosed |
| US-20180194756-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194756-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194756-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-9938260-B2 | Soluble guanylate cyclase activators and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-9938260-B2 | Soluble guanylate cyclase activators and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-9938260-B2 | Soluble guanylate cyclase activators and their use | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| US-20170305888-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| US-20170305888-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| US-20170305888-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-10-26 | — | — | US | disclosed |
| WO-2016042536-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305888-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GUCY1A2, GUCY1A1, GUCY1B1 | GRM1 2234/4885GRM5 1471/4885WNT3A 3081/4885 |
| US-10472350-B2 | Soluble guanylate cyclase activators and their use | GUCY1A2, GUCY1A1, GUCY1B2 | GRM1 2485/4885GRM5 1551/4885WNT3A 3121/4885 |
| US-20180194756-A1 | NOVEL SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND THEIR USE | GUCY1A2, GUCY1A1, GUCY1B1 | GRM1 2234/4885GRM5 1471/4885WNT3A 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.